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Introduction: Conventional systemic therapies for psoriasis are associated
with serious toxicities that can limit long-term use. In recent years, biological
therapies have offered the possibility of long-term therapy with improved
safety and efficacy for the treatment of psoriasis. Biological therapies can be
classified into three categories: the T-cell modulating agents (alefacept and
efalizumab), the inhibitors of TNF-a (adalimumab, etanercept, infliximab)
and the inhibitors of IL-12 and -23 (ustekinumab). Efalizumab is a humanized
recombinant monoclonal IgG1 antibody. It targets multiple stages in the
immunopathogenesis of psoriasis: initial T-cell activation, migration of
T-cells into dermal and epidermal tissues, and T-cell reactivation. On
19 February 2009, the Committee for Medicinal Products for Human Use
(CHMP) recommended the suspension of the marketing authorisation for
efalizumab.
Areas covered: Numerous clinical trials have demonstrated the efficacy, safety
and health-related quality of life benefits of efalizumab in patients with mod-
erate-to-severe chronic plaque psoriasis. Efalizumab was approved by the FDA
in November 2003 and by the European Medicines Evaluation Agency in Sep-
tember 2004 for the treatment of adult patients with moderate-to-severe
chronic plaque psoriasis. Recently, three cases of progressive multifocal
leukoencephalopathy were described in patients on long-term (> 3 years)
efalizumab therapy, leading to its withdrawal from the market.
Expert opinion: Although initially favorable, the safety profile of efalizumab
revealed the appearance of severe adverse events in long-term treated
patients. Therefore, post-marketing surveillance is essential for correct
evaluation of drug potential.
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1. Introduction
Psoriasis is a chronic inflammatory systemic disease affecting between 1 and 3% of
the population in Europe and the US [1,2].
Traditional systemic therapies for psoriasis such as methotrexate, cyclosporin A,
retinoids or psoralen UVA (PUVA) therapy have a potential for long-term
toxicity and may not always provide sufficient improvement of the disease. New
targeted biologic therapies have been developed in response to this unmet
need through an increased understanding of the immunopathological basis
for psoriasis.
Biological therapies for the treatment of psoriasis can be classified into three cat-
egories: the T-cell modulating agents (alefacept and efalizumab), the inhibitors
of TNF-a (TNF-a blockers, e.g., adalimumab, etanercept, infliximab) and the
inhibitors of IL-12 and -23 (e.g., ustekinumab and briakinumab).
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Efalizumab (Raptiva, Genentech, South San Francisco,
CA, USA), a recombinant humanized monoclonal
IgG1 antibody directed against a subunit (CD11a) of
leukocyte function-associated antigen-1 (LFA-1) blocks
LFA-1-mediated T-cell adhesion.
In Phase I and II trials, the pharmacokinetic and pharma-
codynamic effects of efalizumab were determined in psoriasis
patients. Single or multiple doses of efalizumab by intrave-
nous or subcutaneous (s.c.) routes resulted in rapid saturation
of available cell surface CD11a binding sites on T cells and
downregulation of CD11a expression on T lymphocytes in
the dermis, epidermis and in the circulation. These effects
were reversible and once efalizumab was cleared from the cir-
culation, CD11a binding sites return to pretreatment levels
within 10 days [3,4].
In binding to CD11a, efalizumab inhibits the interaction
of LFA-1 with intercellular adhesion molecule-1 (ICAM-1),
and thus blocks multiple key T-cell-mediated events involved
in the immunopathogenesis of psoriasis, including T-cell
activation by the antigen-presenting cell, T-cell adhesion
and trafficking from the circulation into psoriatic lesions,
and T-cell reactivation in psoriatic skin.
Efalizumab is self administered as an s.c. injection as an
initial single 0.7 mg/kg body weight dose followed by weekly
injections of 1 mg/kg body weight [5,6].
Efalizumab was approved by the FDA in November
2003 and by the European Medicines Evaluation Agency in
September 2004 based on studies in ~ 2700 patients, of
whom only 218 were exposed to the drug for > 1 year.
It is approved for the treatment of adult patients
(aged ‡ 18 years) with chronic moderate-to-severe plaque
psoriasis who are candidates for systemic therapy or photo-
therapy (in the US) or who have failed to respond to, have a
contraindication to or are intolerant of other systemic thera-
pies, including cyclosporine (ciclosporin), methotrexate and
PUVA photochemotherapy (in the EU).
In addition to psoriasis, there are many other conditions
that have been presumably successfully treated with this agent,
including pustular psoriasis of the palms and soles, general-
ized granuloma annulare [7], cutaneous lupus erythemato-
sus [8], cutaneous dermatomyositis [9], atopic dermatitis [10]
and alopecia areata [11].
Besides the Phase I and II trial experience, numerous
Phase III clinical trials including four large placebo-
controlled and one 3-year, open-label trial have demonstrated
the efficacy, safety and health-related quality of life benefits of
efalizumab in patients with moderate-to-severe chronic
plaque psoriasis.
Collectively, these trials characterize the response of patients
to short-term (12 weeks), intermediate-term (24 weeks) and
long-term (36 months) efalizumab therapy [12-17].
A post-approval open-label trial (study acronym CON-
TROL II IMP25300) evaluated the efficacy and safety of
efalizumab in the restricted, difficult-to-treat, European-label
and the management of psoriasis rebound and exacerbation
during or after efalizumab treatment [18].
After a single s.c. conditioning dose of efalizumab 0.7 mg/kg,
eligible patients received open-label s.c. efalizumab at a dose of
1 mg/kg once a week for a further 11 weeks, and patients were
classified at week 12 according to the dynamic Physician Global
Assessment (PGA) rating as responders (‘good’, ‘excellent’ or
‘cleared’) or non-responders.
Responders could continue to receive weekly open-
label s.c. efalizumab at 1 mg/kg for up to 8 weeks and
non-responders transitioned to alternative anti-psoriasis
medication or stopped treatment.
Between 13 December 2004 and 12 April 2006, 1266
patients were enrolled in the trial and a total of 688 patients
continued into the efalizumab continuous treatment period
after week 12 (Figure 1).
Among those patients, 79.5% had a PGA rating of ‘good’,
‘excellent’ or ‘cleared’ at week 20.
Psoriasis Area and Severity Index (PASI) by week 12, the
median improvement from baseline in PASI score in the
intent-to-treat (ITT) population, was 68.4% (median PASI
score at baseline of 19.55 and 6 at week 12). The proportion
of patients in the ITT population with a PASI 50/PASI 75/
PASI 90 response increased throughout the first treatment
period to 65.5/35.9/13% at week 12. At week 20, the median
PASI score was 3.90 for patients in the continuous treat-
ment period and the proportion of patients in the ITT
population with a PASI 50/PASI 75/PASI 90 response
increased further through the continuous treatment period
to 78.2/52.9/24.3% of responders at week 20 (Figure 2).
Of the 127 responders at week 12 who discontinued
efalizumab, 11% experienced rebound and 56.7% relapsed
with a median time to relapse of 56 days and this appears sim-
ilar to that observed with methotrexate and cyclosporine [19-23].
Adverse events are summarized in Table 1.
Interestingly, recent data identified genetic markers as a
potential predictor of response to efalizumab.
The presence of the histocompatibility antigen HLA-Cw6
has been associated with the presence of psoriasis and appears
to confer a risk for more severe disease as well as early-
onset psoriasis. Recently, other data suggest that the HLA-
Cw6 polymorphismmay also be capable of predicting response
to some therapies. A study by Gulliver [24] demonstrated that
Article highlights.
. Efalizumab was the first plaque psoriasis-specific
biologic drug.
. This drug has shown a long term favorable efficacy in
about two-thirds of patients.
. Drug-related adverse events were generally mild and
consisted of infections and psoriasis eruptions.
. The occurrence of three cases of progressive multifocal
leukoencephalopathy in long term-treated patients led
to the withdrawal of efalizumab from the market.
This box summarizes key points contained in the article.
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the presence of the HLA-Cw6 allele was predictive of a
response to treatment with efalizumab: all patients possessing
the allele (N = 11) responded to treatment with efalizumab,
compared to only 50% of patients without the allele who
responded to treatment (p = 0.012). Costanzo et al. [25,26]
reproduced this finding, demonstrating that 81.8 and 34.7%
of patients testing positive for the HLA-Cw6 allele achieved
a 50 and 75% improvement in PASI scores (i.e., PASI
50 and PASI 75), respectively, after 12 weeks of efalizumab
therapy. Of patients who lacked the allele, only 58.3%
achieved PASI 50 and 16.7% achieved PASI 75. Interestingly,
presence of the allele was not predictive of a response to
anti-TNF-a therapy, such as etanercept.
The efficacy of efalizumab has been demonstrated both in
clinical trials and in several years of off-trial experience. An
important advantage of efalizumab over other biologic drugs
was the stability and maintenance of clinical response over
time. Also, in recent years, there have been several cases of
successful use of efalizumab in patients with a history of
heart failure [27] and in patients with difficult to treat psoriasis
co-morbidities such as cardiovascular disease, metabolic
syndrome and liver diseases [28].
The same results cannot apparently be obtained with TNF
blocker biologics, which are contraindicated in most of the
morbidities associated with psoriasis [29-31].
2. Acute adverse events
Efalizumab was generally well tolerated with similar incidence
and type of adverse events in previous Phase III clinical trials.
The data from clinical trials indicate that the most
common side effect is an flu-like syndrome that may include
headaches, chills, fever, nausea and myalgia, which usually
occur within 48 h following the first two injections, are
dose-dependent and usually well tolerated at the dose of
0.7 mg/kg [32]. The incidence of such symptoms after the first
injection was 27.4% in the group receiving efalizumab as
compared with 21.2% in the placebo-treated group.
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Figure 1. Proportions of efalizumab patients with a PGA rating of ‘good’, ‘excellent’ or ‘cleared’ by visits at weeks 12 and 20.
PGA: Physician Global Assessment.
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Figure 2. Proportions of patients with PASI 50, PASI 75 and PASI 90 responses.
PASI: Psoriasis Area and Severity Index.
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Paracetamol or ibuprofen is suggested in case of such events or
as premedication [33]. In particular, headaches are the most
common of these side effects, affecting 32% of patients in
clinical trials. The frequency of such symptoms decreased
markedly when the treatment was continued for three or
more injections (3.7% in the efalizumab group vs 3.9% in
the placebo group).
Efalizumab was generally well tolerated during the
36 months of continuous treatment. There was no increase
over time in the overall incidence of adverse events, no
increase in common adverse events, no emergence of new
adverse events, no apparent trend towards an increase in
the incidence of clinically significant adverse events, and no
evidence of cumulative or end-organ toxicity.
Psoriasis adverse events were generally mild or moderate
in severity.
Hamilton analyzed > 3500 patients with psoriasis who have
been treated in 14 efalizumab clinical trials [34]. Importantly,
some of these patients have participated in the longest run-
ning trial in psoriasis patients with any biologic agent: a
recently completed, 36-month, open-label Phase III trial
(ACD2243g). Efalizumab clinical trials have provided investi-
gators substantial experience with efalizumab in patients with
moderate-to-severe psoriasis. As psoriasis fluctuates in sever-
ity, the response to treatment with efalizumab or other psori-
asis therapies can vary widely among patients. Hamilton
assessed that 60 -- 70% of his patients experienced excellent
improvement, achieving a static PGA and observed that the
potential for variability in response to efalizumab therapy is
most evident within the first 3 months after initiation, after
which most patients enter a period of continuous long-
term psoriasis control. During this early treatment window,
patients generally respond in one of three ways: i) patients
respond well to efalizumab without the occurrence of an
intercurrent psoriasis event, ii) the original psoriasis plaques
respond well to therapy but patients develop a transient psori-
asis papular eruption or mild arthropathy during therapy or
iii) patients experience a generalized form of inflammatory
psoriasis instead of showing improvement or develop a signi-
ficant inflammatory arthropathy irrespective of the response
in the skin. As intercurrent psoriasis events generally present
within the first 3 months of initiating efalizumab therapy,
patients should be more closely monitored during this time.
After this time, most of responding patients demonstrate con-
tinuous long-term disease control. Soon after treatment initi-
ation, it is not always clear whether a patient will respond
to therapy. Some patients who respond to efalizumab may
develop a transient localized papular eruption or mild arthro-
pathy. Although infrequent, some patients, generally those
who do not respond to efalizumab, may develop a generalized
inflammatory flare or arthropathy.
Many patients who experience an intercurrent psoriasis
event wish to remain on efalizumab therapy or be retreated
with efalizumab after discontinuation because of improve-
ments in their psoriasis. These patients demonstrate that
the long-term benefits of efalizumab therapy outweigh the
occasional short-term challenge. The temporary addition of
concomitant medications early in therapy and proper patient
education about the long-term durability once response is
attained will result in effective utilization of efalizumab in
the dermatology community [35].
Exacerbation of psoriasis including erythrodermic, guttate
or pustular forms (2.2% in the efalizumab-treated group vs
0.8% in the placebo group) as well as worsening of psoriatic
arthritis (1.6% in the efalizumab-treated group vs 1.3% in
the placebo group) may be observed during treatment with
efalizumab [36].
The most severe of these events is the so-called generalized
inflammatory flare that has been defined as the development
of a flare of inflammatory. In the first 12-week period of
placebo-controlled trials, psoriasis adverse events occurred in
3.2% of efalizumab-treated patients compared with 1.4% in
the placebo group and were predominantly mild to moderate
in severity. This event typically presents as widespread, ery-
thematous, edematous lesions and involves existing plaques.
Generalized inflammatory flares are typically observed in
patients who do not respond to efalizumab therapy and
most often occur in the first 6 -- 10 weeks after initiating
efalizumab and in some cases can be solved by adding a
short course of classic psoriasis systemic therapy to the
biologic agent.
After discontinuation of efalizumab, a significant propor-
tion of patients may experience rebound (defined as PASI
125% of baseline or newly developing pustular or erythroder-
mic psoriasis occurring within 8 weeks of discontinuation).
The incidence of rebound (as defined in the efalizumab anal-
yses) during the 12 weeks after efalizumab discontinuation
in multiple clinical trials was 14%. Less than 1% (0.7%)
Table 1. AE summary of the safety population during
efalizumab treatment.
Numbers of patients (%)
FT period
(N = 1266)
CT period
(N = 688)
Any AE 785 (62) 122 (17.7)
Serious AE 60 (4.79) 10 (1.5)
AE leading to withdrawal 89 (7) 4 (0.6)
Nervous system disorders 355 (28) 9 (1.3)
General disorders and
administration-site conditions
318 (25.1) 10 (1.5)
Infections and infestations 212 (16.7) 35 (5.1)
Musculoskeletal and
connective tissue disorders
176 (13.9) 21 (3.1)
Skin and subcutaneous
tissue disorders
170 (13.4) 32 (4.7)
Gastrointestinal disorders 138 (10.9) 7 (1)
Malignancy 4 (0.3) 0 (0)
Death 1 (0.1) 0 (0)
AE: Adverse event; CT: Continuous treatment; FT: First treatment.
Efalizumab
242 Expert Opin. Drug Saf. (2011) 10(2)
Ex
pe
rt 
O
pi
n.
 D
ru
g 
Sa
f. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f U
lst
er
 a
t J
or
da
ns
to
w
n 
on
 1
1/
28
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
of patients experienced a serious psoriasis adverse event or
a severe adverse event of erythrodermic, pustular or more
inflammatory psoriasis after discontinuation of efalizumab.
Plans for management of flares or a change in character of
the disease should be made at the onset of therapy. Physicians
unwilling to use other systemic agents such as methotrexate,
acitretin or cyclosporin for patients whose disease flares
with efalizumab should perhaps reconsider the use of this
agent [36,37].
Transient papular eruptions are rashes that consist of local-
ized papules and plaques that typically appear during the first
4 -- 8 weeks of efalizumab therapy and frequently present on
the neck, torso and flexural areas, although any body site
can be affected. This reaction has been explained by the
alternative use of surface markers for T-cell trafficking. Histo-
logically, they represent inflammatory psoriatic plaques and
discontinuation of efalizumab is usually not required in these
cases and papules typically clear with continued efalizumab
therapy. Adding a concomitant topical therapy to efalizumab
can help establish control of the eruption [38,39].
Worsening or de novo psoriatic arthritis during or following
efalizumab therapy has also been reported [40].
In the published European ‘CLinical Experience Acquired
with Raptiva’ (CLEAR) study, arthralgia was reported in
7.4% of the patients treated with efalizumab (compared to
3% of those receiving placebo) [41].
Bang and Gniadecki [42] suggested that this phenomenon
could be explained by the mechanism of action of the drug,
which impairs T-lymphocyte trafficking to sites of cutaneous
inflammation. Thus, T cells would be redistributed and
increased in other compartments such as the joints, provoking
the articular response. A previous history of arthropathy
and poor clinical response seem to increase the possibility of
developing articular symptoms [43]. There was, however, no
increased incidence of arthropathy in efalizumab-treated
patients in a long-term study for up to 3 years [44].
Martin et al. [45] presented six cases in which an inflam-
matory flare appeared in a delayed fashion between 23 and
72 weeks after the therapy was started. All six patients
had, until then, been responding to the treatment, with a
dramatic improvement of their psoriasis with efalizumab.
These two characteristics make this event distinctive and
different from what has previously been reported. The pro-
nounced worsening of the cutaneous psoriatic lesions
was accompanied by severe musculoskeletal involvement
in all cases. All of them had chronic, stable moderate-to-
severe plaque psoriasis and had undergone other systemic
therapies before efalizumab. The PASI scores when efalizu-
mab treatment was started ranged from 9 to 20.1 (mean
15.1). The flare started between weeks 23 and 72 and in
all cases arthalgia was also observed. In one of these
patients, scintigraphy showed increased uptake in the joints.
After discontinuation of efalizumab, none of the patients
experienced another episode of arthritis during 18 months
of follow-up.
Relatively uncommon adverse events included urticaria,
rashes and other presumably allergic reactions.
Antibodies directed against efalizumab were detected in
2 -- 6% of patients, apparently without clinical relevance [46,47].
3. Hematologic adverse events
Serious adverse effects are rare and include thrombocytopenia,
hemolytic anemia and infections.
Lymphocytosis (which is sustained during efalizumab
treatment) can be observed in up to 40% of patients and is
presumably because of the specific mode of action of the
compound [47].
Thrombocytopenia (b 52,000 platelets/ml), which again
resolved after discontinuation of efalizumab, was observed in
0.3% of patients in the clinical trials. Significant efalizumab-
associated thrombocytopenia has been documented as causing
petechiae, purpura and bleeding from mucosal membranes.
The initial clinical development trial for efalizumab
involved 2762 patients treated for a minimum of 12 weeks [48].
Platelet count was at or below 52  109 cells/l. Eight (0.3%)
patients developed thrombocytopenia during treatment.
Warkentin and Kwon [49] reviewed all eight cases and
determined that two were unrelated to efalizumab (one
patient had metastatic prostate cancer; one had chronic
thrombocytopenia before efalizumab treatment).
Mapping of the serial platelet counts for each patient
showed that the onset of thrombocytopenia occurred after
8 -- 12 weeks of therapy in 5 of 6 patients. The sixth patient
had been taking efalizumab for longer than 1 year and
developed thrombocytopenia 2 months after valproic acid
was added to the treatment plan.
After efalizumab was discontinued, the thrombocytopenia
resolved in 1 -- 9 weeks in all patients. Their review indica-
ted that the majority of patients with efalizumab-associated
thrombocytopenia will manifest in the first 12 weeks of treat-
ment; thus, the recommendation was to monitor the platelet
count monthly for the first 3 months, then every 3 months
for the remainder of therapy.
However, the case report from Hostetler et al. [50] and two
prospective studies have documented late-onset thrombo-
cytopenia associated with extended efalizumab therapy and
they highlight the need for further laboratory evaluation dur-
ing treatment. Prospective studies of extended efalizumab
therapy, however, indicate that thrombocytopenia may occur
with a later onset. Using a randomized, placebo-controlled
design, Gottlieb et al. [51] followed up 339 patients through
27 months of efalizumab therapy. They reported a mild
decrease in the average platelet count over time, from 265 
109 cells/l before therapy to 235  109 cells/l at month 27.
In any 3-month window during the study, an average of
11 (3.2%) patients were thrombocytopenic on routine moni-
toring. Furthermore, a total of four patients had five mild-to-
severe episodes of symptomatic thrombocytopenia during the
27 months. Episodes occurred after 21 months of efalizumab
Talamonti, Spallone, Di Stefani, Costanzo & Chimenti
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therapy. The thrombocytopenia resolved spontaneously after
discontinuation of efalizumab for every patient in this study
and no patient required corticosteroids.
The substantially increased incidence of thrombocyto-
penia in this study compared with the clinical trial (3.2 vs
0.22 -- 0.3%) is probably related to the more inclusive
definition of thrombocytopenia used in this study (130 
109 cells/l vs 52  109 cells/l).
Another randomized, placebo-controlled study followed
498 patients through 24 weeks of efalizumab therapy [52].
Researchers reported one case of thrombocytopenia that
occurred after 16 weeks of efalizumab therapy. This
patient had a nadir of 52  109 cells/l and recovered fully
with discontinuation of efalizumab and a short course of
corticosteroids.
Unfortunately, other studies of extended efalizumab ther-
apy have not reported the incidence or timing of thrombocy-
topenia. Additionally, no study reporting thrombocytopenia
documented whether these patients had a different likelihood
of responding to efalizumab clinically compared with patients
without significant adverse events [52-54]. This case prompted
us to review the data on efalizumab-associated thrombo-
cytopenia. Although the data are sparse, this case report
and several prospective trials suggest that the highest risk
period for onset of efalizumab-associated thrombocytopenia
is 8 -- 16 weeks after therapy is initiated.
The most likely mechanism of thrombocytopenia is a
drug-induced autoantibody against a component of the plate-
let membrane, although such antibody(ies) have not been spe-
cifically demonstrated in any case of efalizumab-induced
thrombocytopenia.
The mechanism for the hematological toxicity is not clear,
but it is advised that patients be monitored monthly during
the first 3 months of therapy. This recommendation is based
on the initial clinical trial for efalizumab that indicated most
episodes of thrombocytopenia occurred in the first 12 weeks
of therapy [55].
Four cases of hemolytic anemia have been reported with
efalizumab. Two cases were reported during clinical trials
and occurred between 4 and 6 months after initiation of
therapy. These cases were associated with a decrease in hemo-
globin level to 6 and 7 g dl, requiring discontinuation of
therapy and transfusion.
The other two cases of hemolytic anemia occurred
post-marketing and little information is available on these
cases [56,57].
Tom et al. also reported the first case of
efalizumab-associated immune-mediated pancytopenia [58].
The case represents the first known reported case of
efalizumab-associated pancytopenia. Noticeably, the findings
were consistent with an immune-mediated mechanism caus-
ing pancytopenia, with hemolysis in the presence of a red-
cell autoantibody, neutropenia and thrombocytopenia with
adequate marrow megakaryocytes but refractory to platelet
transfusions. The hemolysis may have been amplified by an
inadequate marrow response, resulting in significant anemia.
The prompt response of the patient’s thrombocytopenia
to immunomodulation (IVIG and prednisone) was also
consistent with an immune-mediated process.
The exact role of efalizumab in the development of autoim-
mune pancytopenia is not clear. Drug-induced autoantibodies
may recognize combinatorial epitopes formed by drug bind-
ing to a membrane glycoprotein (example: quinine) or a con-
formational change in a glycoprotein induced by drug
binding at a different cell membrane site (example: tirofiban).
Some drugs, such as gold salts, may perturb the immune
response such that autoantibodies to a glycoprotein are
generated without the need for simultaneous drug binding
(drug-independent antibodies) [59].
A case of autoimmune agranulocytosis with granulocyte-
bound and neutrophil specific-bound antibodies has been
reported with infusion of infliximab. Infliximab is a chimeric
(human and murine) mAb that binds to and blocks the effects
of TNF-a. Cytopenia has also been reported with other
TNF-a blockers, but it is unclear whether this is secondary
to the immunogenicity of the molecules themselves or second-
ary to TNF-a blockade as this cytokine affects hematopoietic
stem cell differentiation [60,61]. In the case of efalizumab, a
direct drug effect is unlikely. CD11a is found not only on
lymphocytes but also on neutrophils and activated platelets
[57-62]. However, given its absence on mature erythrocytes,
antibodies recognizing efalizumab binding to CD11a would
not fully explain the pancytopenia in this case. Induction of
drug-independent autoantibodies that affected all three cell
lines appears to be a more plausible mechanism.
4. The risk of tumor and infections
Given that serious infections or the risk of tumor develop-
ment are general concerns with immunomodulating thera-
pies, these parameters have been extensively studied in
efalizumab-treated patients.
In a pooled analysis of multiple Phase III open-label
and placebo-controlled clinical trials, it was found that
efalizumab by itself does not increase a patient’s risk for
malignancy [63,64].
However, the incidence of non-melanoma skin cancer,
including basal cell and squamous cell carcinomas, seems
to be slightly elevated in efalizumab recipients with signs of
sun damage and/or history of PUVA treatment [65,66].
In a review of malignancies observed with efalizumab,
Leonardi et al. [63] pooled patient data from 14 Phase III
placebo-controlled, open-label clinical trials involving
2980 patients treated with efalizumab. In patients treated
with efalizumab, three cases of LPD were reported in
2558 patient-years of follow-up, yielding an incidence rate
of 0.12/100 patient-years.
Only a few isolated case reports have been docu-
mented reporting the association of efalizumab with
lymphomas [67-69].
Efalizumab
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Because many therapies for psoriasis disrupt the normal
inflammatory cascade and could theoretically impair the
body’s ability to respond to external pathogens, a possible
increase in the incidence of infection is a concern with any
new psoriasis therapy that affects the immune system. Immu-
nologic events are pivotal in the initiation of psoriasis and
required for the continued expression of psoriasis symp-
toms [70,71]. Specifically, aberrant interactions between acti-
vated T cells and keratinocytes result in the keratinocyte
proliferation and differentiation characteristic of psoriasis.
A literature search using MEDLINE (key terms: psoriasis,
infection, risk and rate; years: 1995 -- 2005) revealed that
little research is available concerning the underlying risk
for infection in patients with psoriasis. However, it is
known that with immunosuppression, there is potential
for new-onset infections or reactivation of latent infections,
and opportunistic infections are of concern when any
immunosuppressive therapy is administered.
For example, studies have shown that cyclosporine can be
associated with influenza-like symptoms (9.9%) and upper
respiratory tract infections (7.7%) when administered to
patients with psoriasis. It has also been found that methotrex-
ate might cause leukopenia that could reduce resistance to
infection [72]. An important advance in the management
of psoriasis has been the development of targeted biologic
therapies made possible by an improved knowledge of the
pathogenesis of psoriasis. Still, biologic agents are immuno-
suppressants that target cytokines or specific immune cell
subpopulations. The long-term safety profiles of biologic
therapies are being assessed in patients with psoriasis. There
remains a concern that, as with any immunosuppressant,
biologic therapies might reduce resistance to infection. For
example, TNF-a is important in host defense against infec-
tion [73,74] and inhibitors of this cytokine have been associated
with cases of tuberculosis (TB) reactivation. Likewise, T cells
are crucial to the immune response [75]; thus, their reduction
or inhibition could theoretically increase the risk for infection.
Efalizumab reversibly blocks LFA-1 and is not associated
with lymphocyte depletion. In clinical studies, a trend toward
increased mean circulating lymphocyte counts was shown
during efalizumab therapy, but the counts remained within
normal ranges. The elevation was most likely due to the inhi-
bition of T-cell trafficking from the circulation into inflamed
skin. Leukocyte counts returned to baseline after efalizumab
discontinuation [76-79].
Because efalizumab, like all biologic therapies for psoriasis,
alters the normal inflammatory cascade and could, therefore,
impair the body’s ability to respond to external pathogens, it
was important to assess the incidence of infection in patients
receiving efalizumab therapy in the clinical trials.
During the first 12 weeks of treatment, the overall inci-
dence of infection in the efalizumab-treated group was statis-
tically similar to that of the placebo group (28.6 vs 26.3%).
The majority of infections were considered mild-to-moderate
in intensity. Serious infections requiring hospitalization
occurred infrequently during the efalizumab trials. Of 2475
efalizumab-treated patients, 27 (1.1%) were hospitalized
because of infection. During controlled trials, 2 of 715
(0.3%) patients receiving placebo were hospitalized because
of serious infection; one of the two events occurred during
the post treatment follow-up period.
No clear correlation was found between efalizumab treat-
ment and any particular type of infection requiring hospitali-
zation. The serious infections resolved in 26 of 27 (96.3%)
efalizumab-treated patients, with 1 patient being lost to
follow-up. In all, 10 of 2475 (0.4%) efalizumab-treated
patients discontinued treatment because of a serious infection
requiring hospitalization.
Serious infections requiring hospitalization included
cellulitis, pneumonia, abscess, sepsis, bronchitis, gastroenteri-
tis, aseptic meningitis, Legionnaire’s disease and vertebral
osteomyelitis.
During the efalizumab clinical trials, no clear increase was
found in the frequency or severity in the types of infection
commonly observed in immunocompromised individuals,
including HSV and HZV infection or reactivation [79]. No
evidence of systemic dissemination, as might be observed in
immunosuppressed hosts, was found.
Long-term treatment appeared to effect no increase in the
risk for infection (Table 2) [80].
Based on all clinical data available thus far, it appears that
both the risk of increased infection rates and the development
of malignant tumors are similar in patients with psoriasis
treated with efalizumab and the general population of patients
with psoriasis.
In particular, in clinical trials, there was no increased risk
for opportunistic infections (including TB) during treatment
periods of up to 3 years. However, the use of clinical trial
data can be limited by ascertainment bias, use of homoge-
neous populations, limited co-morbid diseases, small numbers
of patients and short trial duration. In addition, patients with
a history of or ongoing uncontrolled bacterial, viral, fungal or
atypical mycobacterial infection; a history of opportunistic
infections (e.g., systemic fungal infections, parasites) or a his-
tory of active TB; patients who were undergoing treatment for
TB; and patients with seropositivity for HBV and HCV or
HIV were excluded from the clinical trials [80,81].
However, opportunistic infections have been reported in
the post-marketing surveillance in patients with psoriasis
receiving efalizumab. Four cases of efalizumab-induced asep-
tic meningitis have been reported: two cases were mentioned
in a review of events reported during clinical trials [82]
and two cases were reported by Kluger et al. [83] and
Rivas-Rodrı´guez et al. [84].
Kluger et al. [83] reported the first detailed case of aseptic
meningitis induced by efalizumab. Forty-eight hours after
the injection of efalizumab day at a dose of 0.7 mg/kg, a
32-year-old patient with a 14-year medical history of
severe psoriasis experienced severe headaches of increasing
intensity, later complicated by photophobia, phonophobia
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and neck stiffness. Neurological examination revealed nuchal
rigidity. Except for widespread psoriasis lesions, no other
skin eruption or reaction at the site of efalizumab injection
was observed.
A diagnosis of efalizumab-induced aseptic meningitis was
established. The arguments supporting a correlation between
meningitis and efalizumab injection included: i) rapid devel-
opment of symptoms within 48 h after the onset of treatment;
ii) negative findings from extensive investigations for infec-
tious agents; iii) absence of other causes of meningitis and
iv) reversibility after discontinuation of the drug.
Drug-induced aseptic meningitis (DIAM) is an uncommon
adverse reaction mainly caused by NSAIDs, antibiotics, intra-
venous immunoglobulins, mAbs (OKT3 antibodies, inflixi-
mab), intrathecal agents and vaccines. Of note, it appears
that patients with autoimmune diseases are more susceptible
to develop DIAM. The patient presented autoimmune
hyperthyroidism, although this association might have
been fortuitous.
The pathogenic mechanisms remain unknown, although
an immunological type III or IV hypersensitivity is suspected
when the drug has not been directly introduced into the
CSF [85]. In the skin, efalizumab blocks the binding of
LFA-1 to ICAM-1. In the CNS, ICAM-5 (telencephalin),
expressed by neurones of the mammalian brain, is of major
importance for leucocyte binding to neurones. ICAM-5 binds
specifically to the leucocyte integrin CD11a/CD18 and
antibodies against CD11a/CD18 can disrupt this inter-
action [86]. Thus, the aseptic meningitis could be a conse-
quence of the blocking of LFA-1 and ICAM-5 interaction
by efalizumab. Another mechanism might be that efalizumab
binds to a crossreacting neural antigen, thereby, inciting
local inflammation, as suspected by some authors for
OKT3 antibodies [85].
Table 2. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
Controlled trials (weeks 1 -- 12) Extended treatment
Efalizumab
(N = 1620)
Placebo
(N = 715)
Weeks 1 -- 12
(N = 1713)
Weeks 13 -- 24
(N = 1115)
$ 12 Weeks
(N = 1166)
Serious infection, % (95% CI) 0.4 (0.2 -- 0.9) 0.1 (0 -- 0.8) 0.4 (0.2 -- 0.8) 0.3 (0.1 -- 0.8) 0.7 (0.3 -- 1.3)
Diagnosed infection-related
AEs leading to withdrawal %
(95% CI)
0.4 (0.2 -- 0.9) 0.4 (0.1 -- 1.2) 0.5 (0.2 -- 0.9) 0.4 (0.1 -- 1) NR
All diagnosed infection-related
AEs (95% CI)
28.6 (26.4 -- 30.9) 26.3 (23.1 -- 29.7) 28.9 (26.8 -- 31.1) 27.3 (24.7 -- 30) 20.9 (18.6 -- 23.4)
Diagnosed infection %
Nonspecific infection 13.9 15.4 14.5 15 11.8
HSV 4.6 3.4 4.6 3.4 1.9
Gastroenteritis 2.1 3.4 1.3 1.6 0
Infection viral 1.9 1.1 1.8 0.7 0.7
Bronchitis 1.7 1.3 1.8 2 2.2
Urinary tract infection 1.4 1.3 1.8 1.7 1.2
Otitis media 1.4 1.3 1.6 2 1.4
Infection, bacterial 1.2 0.6 1.1 0.8 0.7
Fungal dermatitis 0.9 0.1 1.1 1 0.4
Cellulitis 0.8 0.4 1.1 0.4 0.3
Periodontal abscess 0.6 0.3 0.5 0.4 0.3
Infection, fungal 0.4 0 0.6 0.4 0.5
Pneumonia 0.4 0.3 0.4 0.3 0.3
Furuncolosis 0.4 0.4 0.5 0.8 < 0.1
Abscess 0.2 0 0.3 0.2 0.2
HZV 0.2 0 0.2 0.5 0.2
Vaginalis moniliasis 0.2 0.1 < 0.1 < 0.1 0.3
Infection, parasitic 0.1 0 0.1 0 < 0.1
Oral moniliasis 0.1 0 0.1 < 0.1 < 0.1
Hepatitis < 0.1 0 0.1 < 0.1 -
Auxiliary moniliasis < 0.1 0 < 0.1 0
Sepsis < 0.1 0 0 0 02.2
Meningitis < 0.1 0 < 0.1 0 -
Moniliasis, unspecified 0 0.1 0 0 -
Peritonitis 0 0 0 0 < 0.1
Osteomyelitis 0 0 0 0 < 0.1
Pyelonephritis 0 0 0 < 0.1 0.2
HSV: Herpes simplex virus; HZV: Herpes zoster virus.
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The physician should be alerted by unusually severe head-
aches. Efalizumab-induced meningitis may not be rare but
simply under-recognized given that headaches commonly
occur during this treatment.
One case of transverse myelitis was observed during the
clinical development program (2762 efalizumab-treated
patients) and neurologic events, including cases of Guillain--
Barre´ syndrome, chronic inflammatory demyelinating
polyneuropathy, facial palsy and transverse myelitis, have
been observed in patients receiving efalizumab in the
post-marketing setting [87].
A recent case of visceral leishmaniasis infection has been
reported underscoring that visceral leishmaniasis should be
taken into account during efalizumab treatment, at least for
patients living in endemic areas [88].
A disseminated eruptive giant molluscum contagiosum [89]
and a case of CMV colitis [90] have been reported recently
under efalizumab treatment too.
Opportunistic infections have been reported in the post-
marketing surveillance in patients with psoriasis receiving
efalizumab. In particular, cases of JC virus infection resulting
in progressive multifocal leukoencephalopathy (PML) have
been reported in patients receiving efalizumab continuously
for > 3 years.
PML, a usually fatal demyelinating disorder, results from
infection with a ubiquitous polyoma virus and can occur in
patients with severe immunosuppression. This polyoma virus
was named JC virus by Padgett et al., based on the initials
of the patient from whom the virus was first isolated in
1971 [91-93].
The prevalence of PML in the general population was esti-
mated at 4.4 cases/100,000 individuals, according to data
from a medical service and out-patient prescription claims
database [94]. In recent years, PML is reported in patients
who have received mAbs including natalizumab for MS and
Crohn’s disease [95-97], rituximab for lupus [98] and efalizumab
for psoriasis [99-100].
The mechanism of PML development after mAb treatment
remains controversial, although for natalizumab and efalizu-
mab, inhibition of T-lymphocyte trafficking into the CNS is
thought to be responsible, at least in part.
On 19 February 2009, after > 46,000 patients were exposed
to efalizumab, the Committee for Medicinal Products for
Human Use issued an opinion recommending the suspension
of the marketing authorization for efalizumab in all member
states in which the product was marketed, as its benefits in
the treatment of psoriasis were modest, while there was a
risk of serious side effects. The recommendation was based
on a re-evaluation of the benefit:risk ratio after the occurrence
of three confirmed and one suspected case of PML.
The PML appeared in patients who were 47 -- 73 years.
Two of the patients with confirmed PML and one patient
with possible PML died. All patients belonged to the
3000 patients’ cohort reaching three or more years of
continuous therapy with efalizumab. Furthermore, the
manufacturer Genentech, Inc. has voluntarily withdrawn
efalizumab from the US market as of April 2009.
5. Expert opinion
Efalizumab represents the prototype of T-cell targeted therapy
in psoriasis. The efficacy and safety of efalizumab have
been demonstrated both in clinical trials and in several
years of off-trial experience. Efalizumab showed an efficacy
in ~ 60% of treated patients, defined as responders. In these
patients, efalizumab led to an almost complete clearance of
skin lesions that was maintained long term in the vast major-
ity of responders. The long-term efficacy and stability of
response to efalizumab were peculiar features of this drug.
Different from patients treated with anti-TNF drugs who
often show relapses of the disease during the course of ther-
apy, patients under long-term efalizumab never experience
relapses. This correlates with a great improvement in quality
of life indexes.
The second important point to consider is related to the
safety: contrary to what is expected for a T-cell targeting
immunosuppressive drug, the number of infectious adverse
events observed during trials and in post-trial clinical
use was surprisingly low. There were no signals for bacterial
or common viral infections or opportunistic infections
specifically associated with efalizumab treatment. In the
same line proceeds the lack of significantly increased
risk for neoplasms (excepting the slight increase in
cutaneous neoplasms).
However, the adverse event leading to efalizumab with-
drawal was the diagnosis of three cases of PML, a fatal neuro-
logic disease caused by the reactivation of JC virus in the
brain. This virus, which is present in a large proportion of
population in inactive status, is reactivated following immu-
nosuppression and leads to a progressive demyelinating dis-
ease resulting in death. The mechanisms of virus reactivation
are largely unknown. Because cases of PML were observed
in patients treated with drugs affecting T-cell trafficking
(natalizumab and efalizumab), it is reasonable to hypothesize
that specific subsets of T cells are required to control virus
reactivation. Similarly, because this virus is reactivated
only in a very small proportion of immunodepressed patients,
other factors, for example, genetic background, besides
immunosuppression, are likely to be required for virus reacti-
vation. A strong research effort is, therefore, necessary to iden-
tify the exact mechanisms underlying JC virus reactivation
and patients at high risk of reactivation.
This will allow designing T-cell targeting drugs which leave
intact the capability of immune system to control JC virus
reactivation and to avoid T-cell targeting therapies in high
risk patients.
Based on our personal experience, efalizumab gave us two
main lessons: i) long-term continuous treatment of psoriasis
is the preferable mode of treatment in moderate-to-severe
plaque psoriasis, ensuring the maximum benefit for patients
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and ii) off-trial long term monitoring of adverse events is the
key to evaluate the safety of psoriasis drugs.
In conclusion, we think that efalizumab represented a proof
of principle confirming the effectiveness of T-cell targeting
strategy for the treatment of psoriasis indicating that more
research is needed to bypass potential risks linked to this
therapeutical strategy. It is, therefore, possible that new
advanced T-cell targeting drugs will be added to the psoriasis
armamentarium in the near future.
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